Skip to main content

Table 3 Treatment profiles

From: Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer

Tumor response

n (%)

 CR

1 (2.8)

 PR

19 (52.8)

 SD

13 (36.1)

 PD

0 (0)

 Not evaluated

3 (8.3)

 Response rate (CR + PR)

20 (55.6)

 Disease control rate (CR + PR + SD)

33 (91.7)

  1. CR complete response, PR partial response, SD stable disease, PD progressive disease
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us